File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1097/01.sla.0000245829.00977.45
- Scopus: eid_2-s2.0-34249316548
- PMID: 17522506
- WOS: WOS:000246873000001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma
Title | A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma |
---|---|
Authors | |
Issue Date | 2007 |
Publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.annalsofsurgery.com |
Citation | Annals Of Surgery, 2007, v. 245 n. 6, p. 831-842 How to Cite? |
Abstract | OBJECTIVE: We conducted a randomized controlled trial of adjuvant interferon therapy in patients with predominantly hepatitis B-related hepatocellular carcinoma (HCC) to investigate whether the prognosis after hepatic resection could be improved. SUMMARY BACKGROUND DATA: Recurrence is common after hepatic resection for HCC. Interferon possesses antiviral, immunomodulatory, antiproliferative, and antiangiogenic effects and may be an effective form of adjuvant therapy. PATIENTS AND METHODS: Since February 1999, patients with no residual disease after hepatic resection for HCC were randomly assigned with stratification by pTNM stage to receive no treatment (control group), interferon alpha-2b 10 MIU/m (IFN-I group) or 30 MIU/m (IFN-II group) thrice weekly for 16 weeks. Enrollment to the IFN-II group was terminated from January 2000 because adverse effects resulted in treatment discontinuation in the first 6 patients. By June 2002, 40 patients each had been enrolled into the control group and IFN-I group. The baseline clinical, laboratory, and tumor characteristics of both groups were comparable. RESULTS: The 1- and 5-year survival rates were 85% and 61%, respectively, for the control group and 97% and 79%, respectively, for the IFN-I group (P = 0.137). After adjusting for the confounding prognostic factors in a Cox model, the relative risk of death for interferon treatment was 0.42 (95% CI, 0.17-1.05; P = 0.063). Exploratory subset analysis showed that adjuvant interferon had no survival benefit for pTNM stage I/II tumor (5-year survival 90% in both groups; P = 0.917) but prevented early recurrence and improved the 5-year survival of patients with stage III/IVA tumor from 24% to 68% (P = 0.038). CONCLUSION: In a group of patients with predominantly hepatitis B-related HCC, adjuvant interferon therapy showed a trend for survival benefit, primarily in those with pTNM stage III/IVA tumors. Further larger randomized trials stratified for stage are needed. © 2007 Lippincott Williams & Wilkins, Inc. |
Persistent Identifier | http://hdl.handle.net/10722/88584 |
ISSN | 2023 Impact Factor: 7.5 2023 SCImago Journal Rankings: 2.729 |
PubMed Central ID | |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lo, CM | en_HK |
dc.contributor.author | Liu, CL | en_HK |
dc.contributor.author | Chan, SC | en_HK |
dc.contributor.author | Lam, CM | en_HK |
dc.contributor.author | Poon, RTP | en_HK |
dc.contributor.author | Ng, IOL | en_HK |
dc.contributor.author | Fan, ST | en_HK |
dc.contributor.author | Wong, J | en_HK |
dc.date.accessioned | 2010-09-06T09:45:18Z | - |
dc.date.available | 2010-09-06T09:45:18Z | - |
dc.date.issued | 2007 | en_HK |
dc.identifier.citation | Annals Of Surgery, 2007, v. 245 n. 6, p. 831-842 | en_HK |
dc.identifier.issn | 0003-4932 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/88584 | - |
dc.description.abstract | OBJECTIVE: We conducted a randomized controlled trial of adjuvant interferon therapy in patients with predominantly hepatitis B-related hepatocellular carcinoma (HCC) to investigate whether the prognosis after hepatic resection could be improved. SUMMARY BACKGROUND DATA: Recurrence is common after hepatic resection for HCC. Interferon possesses antiviral, immunomodulatory, antiproliferative, and antiangiogenic effects and may be an effective form of adjuvant therapy. PATIENTS AND METHODS: Since February 1999, patients with no residual disease after hepatic resection for HCC were randomly assigned with stratification by pTNM stage to receive no treatment (control group), interferon alpha-2b 10 MIU/m (IFN-I group) or 30 MIU/m (IFN-II group) thrice weekly for 16 weeks. Enrollment to the IFN-II group was terminated from January 2000 because adverse effects resulted in treatment discontinuation in the first 6 patients. By June 2002, 40 patients each had been enrolled into the control group and IFN-I group. The baseline clinical, laboratory, and tumor characteristics of both groups were comparable. RESULTS: The 1- and 5-year survival rates were 85% and 61%, respectively, for the control group and 97% and 79%, respectively, for the IFN-I group (P = 0.137). After adjusting for the confounding prognostic factors in a Cox model, the relative risk of death for interferon treatment was 0.42 (95% CI, 0.17-1.05; P = 0.063). Exploratory subset analysis showed that adjuvant interferon had no survival benefit for pTNM stage I/II tumor (5-year survival 90% in both groups; P = 0.917) but prevented early recurrence and improved the 5-year survival of patients with stage III/IVA tumor from 24% to 68% (P = 0.038). CONCLUSION: In a group of patients with predominantly hepatitis B-related HCC, adjuvant interferon therapy showed a trend for survival benefit, primarily in those with pTNM stage III/IVA tumors. Further larger randomized trials stratified for stage are needed. © 2007 Lippincott Williams & Wilkins, Inc. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Lippincott Williams & Wilkins. The Journal's web site is located at http://www.annalsofsurgery.com | en_HK |
dc.relation.ispartof | Annals of Surgery | en_HK |
dc.rights | This is a non-final version of an article published in final form in Annals of Surgery, 2007, v. 245 n. 6, p. 831-842 | en_HK |
dc.subject.mesh | Antineoplastic Agents - adverse effects - therapeutic use | - |
dc.subject.mesh | Carcinoma, Hepatocellular - drug therapy - pathology - surgery - virology | - |
dc.subject.mesh | Interferon-alpha - adverse effects - therapeutic use | - |
dc.subject.mesh | Liver Neoplasms - drug therapy - pathology - surgery - virology | - |
dc.subject.mesh | Proportional Hazards Models | - |
dc.title | A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0003-4932&volume=245&issue=6&spage=831&epage=842&date=2007&atitle=A+randomized,+controlled+trial+of+postoperative+adjuvant+interferon+therapy+after+resection+of+hepatocellular+carcinoma | en_HK |
dc.identifier.email | Lo, CM: chungmlo@hkucc.hku.hk | en_HK |
dc.identifier.email | Chan, SC: chanlsc@hkucc.hku.hk | en_HK |
dc.identifier.email | Poon, RTP: poontp@hku.hk | en_HK |
dc.identifier.email | Ng, IOL: iolng@hku.hk | en_HK |
dc.identifier.email | Fan, ST: stfan@hku.hk | en_HK |
dc.identifier.email | Wong, J: jwong@hkucc.hku.hk | en_HK |
dc.identifier.authority | Lo, CM=rp00412 | en_HK |
dc.identifier.authority | Chan, SC=rp01568 | en_HK |
dc.identifier.authority | Poon, RTP=rp00446 | en_HK |
dc.identifier.authority | Ng, IOL=rp00335 | en_HK |
dc.identifier.authority | Fan, ST=rp00355 | en_HK |
dc.identifier.authority | Wong, J=rp00322 | en_HK |
dc.description.nature | link_to_OA_fulltext | en_US |
dc.identifier.doi | 10.1097/01.sla.0000245829.00977.45 | en_HK |
dc.identifier.pmid | 17522506 | - |
dc.identifier.pmcid | PMC1876947 | - |
dc.identifier.scopus | eid_2-s2.0-34249316548 | en_HK |
dc.identifier.hkuros | 127612 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-34249316548&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 245 | en_HK |
dc.identifier.issue | 6 | en_HK |
dc.identifier.spage | 831 | en_HK |
dc.identifier.epage | 842 | en_HK |
dc.identifier.eissn | 1528-1140 | - |
dc.identifier.isi | WOS:000246873000001 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Lo, CM=7401771672 | en_HK |
dc.identifier.scopusauthorid | Liu, CL=7409789712 | en_HK |
dc.identifier.scopusauthorid | Chan, SC=7404255575 | en_HK |
dc.identifier.scopusauthorid | Lam, CM=36799183200 | en_HK |
dc.identifier.scopusauthorid | Poon, RTP=7103097223 | en_HK |
dc.identifier.scopusauthorid | Ng, IOL=7102753722 | en_HK |
dc.identifier.scopusauthorid | Fan, ST=7402678224 | en_HK |
dc.identifier.scopusauthorid | Wong, J=8049324500 | en_HK |
dc.identifier.issnl | 0003-4932 | - |